Drug Profile
CS 712
Alternative Names: CS-712; R-133663Latest Information Update: 12 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antiallergics; Peptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 05 Nov 2004 Phase-II clinical trials in Allergy in Japan (PO)
- 14 Jun 2004 This compound is still in active development